Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 5/20 | 0.38 |
| ▸ | PTGES2 | Q9H7Z7 | 3/20 | 0.38 |
| ▸ | VEGFA | P15692 | 1/20 | 0.38 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1082080 | 0.85 | TRPV4 (0.61) | TRPV4HRH4SLC22A12EPAS1VEGFA | |
| SCHEMBL10034994 | 0.80 | PKM (0.53) | TRPV4CA1CA2CA9CA12 | |
| SCHEMBL29843178 | 0.76 | ALPL (0.52) | HRH4CA1CA2CA9CA12 | |
| SCHEMBL1542154 | 0.76 | ALPL (0.52) | HRH4CA1CA2CA9CA12 | |
| SCHEMBL3020619 | 0.76 | PGR (0.64) | — | |
| SCHEMBL1038946 | 0.76 | HRH4 (0.41) | TRPV4HRH4EPAS1VEGFADDR1 | |
| SCHEMBL224235 | 0.76 | HRH4 (0.49) | TRPV4HRH4 | |
| SCHEMBL3644863 | 0.76 | APP (0.44) | TRPV4HRH4CA2CA9CA12 | |
| SCHEMBL28856969 | 0.74 | CA2 (0.41) | CA1CA2CA9CA12PTGES2 | |
| SCHEMBL30034664 | 0.74 | TRPV4 (0.46) | TRPV4CA1CA2CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087491-A1 | POLYCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-08 | — | — | US | disclosed |
| EP-2081916-A1 | OXADIAZOLE DERIVATIVES WITH ANTI-INFLAMMATORY AND IMMUNOSUPPRESSIVE PROPERTIES | Novartis AG (CH) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008037476-A1 | OXADIAZOLE DERIVATIVES WITH ANTI-INFLAMMATORY AND IMMUNOSUPPRESSIVE PROPERTIES | NOVARTIS AG (CH) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087491-A1 | POLYCYCLIC COMPOUNDS | CD4, HLA-DRB1, MALT1 | TRPV4 2340/4885HRH4 266/4885CA1 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.